Simultaneously, the synergistic effect of RT combined with niraparib fosters an anti-tumor immune response by augmenting CD8+ T lymphocyte infiltration and activating the STING-TBK1-IRF3 pathway [54]. Here, STING1 is linked to neoplasm.